Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Corcoran

Showing results (571-580 of 741) with videos related to

Pageof 75
Sort By:
Science (New York, N.Y.)|May 15, 2025
Precise targeting of HIV broadly neutralizing antibody precursors in humansTom G Caniels, Madhu Prabhakaran, Gabriel Ozorowski, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
JAMA Psychiatry|October 11, 2023
Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis, Shalaila S Haas, Ruiyang Ge, et al.
Cancer Discovery|February 13, 2025
The Germline and Somatic Origins of Prostate Cancer HeterogeneityTakafumi N Yamaguchi, Kathleen E Houlahan, Helen Zhu, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Normative modeling of brain morphometry in Clinical High-Risk for PsychosisShalaila S Haas, Ruiyang Ge, Ingrid Agartz, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
HGG Advances|January 7, 2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to TreatmentYu Jiang, Travis J Meyers, Adaeze A Emeka, et al.
Pageof 75

Showing results (571-580 of 741) with videos related to

Sort By:
Pageof 75
Science (New York, N.Y.)|May 15, 2025
Precise targeting of HIV broadly neutralizing antibody precursors in humansTom G Caniels, Madhu Prabhakaran, Gabriel Ozorowski, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
JAMA Psychiatry|October 11, 2023
Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis, Shalaila S Haas, Ruiyang Ge, et al.
Cancer Discovery|February 13, 2025
The Germline and Somatic Origins of Prostate Cancer HeterogeneityTakafumi N Yamaguchi, Kathleen E Houlahan, Helen Zhu, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Normative modeling of brain morphometry in Clinical High-Risk for PsychosisShalaila S Haas, Ruiyang Ge, Ingrid Agartz, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
HGG Advances|January 7, 2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to TreatmentYu Jiang, Travis J Meyers, Adaeze A Emeka, et al.
Pageof 75